Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell(University of California, Los Angeles), Hany Elsaleh(Australian National University), M. López García(Thomas Jefferson University), Raymond Lai(University of Alberta), Ali Ammar(Northwestern University), William F. Regine(University of Maryland, Baltimore), Ross A. Abrams(Rush University Medical Center), Al B. Benson(Northwestern University), John S. Macdonald(Australian National University), Carol E. Cass(University of Alberta), Adam P. Dicker(Thomas Jefferson University), John R. Mackey(University of Alberta)
Cited by 448Open Access
Abstract
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al.|Journal of Clinical Oncology|1997|5.9k